Global Commercial Director, Breast Cancer Launches

ROLE SUMMARY

Pfizer Commercial Oncology is introducing the world to the next era of cancer care. With a growing portfolio of novel therapies, industry-leading R&D, and a goal of delivering eight breakthroughs by 2030 across major cancer types, we're translating cutting-edge science into market-shaping impact. Here, you'll partner with exceptional colleagues across scientific, medical, and manufacturing teams, backed by advanced digital and AI-enabled infrastructure and the authority to accelerate medicines from discovery to delivery. Guided by our values of courage, excellence, equity, and joy, you'll have the opportunity to stretch your skills and build a career that evolves with you—across teams, roles, and the Pfizer enterprise. Join us to make history — for patients, for their families, for the future. 

At Pfizer Oncology, we are committed to “Outdo Cancer” by advancing transformative medicines wherever we can make a profound difference in the lives of patients. Today, Pfizer Oncology has an industry-leading pipeline that includes a portfolio across breast, genitourinary (GU), hematology-oncology and Precision Medicine areas.

On the heels of our success with IBRANCE, the growing Breast Cancer portfolio continues to accelerate with the development of multiple assets, including our KAT6 inhibitor, prifetrastat, and next-generation CDK4 inhibitor, atirmociclib.

This is a leadership role that requires developing and implementing market winning launch strategies in an increasingly crowded market. The position commands a candidate with strong cross-functional leadership who can be a change agent for the next wave of breast cancer launches.

ROLE RESPONSIBILITIES

• Champion and synthesize customer insights and translate key critical insights into Global strategy and action plans. Lead the development and implementation of key strategic initiatives working closely with US and ex-US colleagues, cross-functional partners in Medical, Legal, Regulatory, GASP, and Business Analytics.

Launch Leadership

• Co-lead the launch strategy for prifetrastat in 2L+

• Elevate differentiation for a new, novel MOA into a crowded landscape

• Advance co-positioning of breast cancer assets and indications across the portfolio

• Go-to-market redesign: partner with regions and countries to upgrade the GTM model to one that embraces and leverages the role of AI across key customer segments, Physicians, Patients, and Caregivers

KAT6 Market Development

• Design and launch the KAT6 Global Market Development Plan for prifetrastat. Drive coordination of the market development strategy (in partnership with atirmociclib) at the global, regional and local levels and ensure consistency of approach and implementation

• Set market development engagement priorities by stakeholder (HCP/Oncology/Urology/Nurses/Payers and Patients)

• Define market development success metrics and KPIs for tracking impact and progress

• Manage agency and vendor partnership efforts pertaining to the design, development and execution of all critical market development assets

Biomarker Testing Lead

• Develop and implement global biomarker testing strategy and initiatives in breast cancer

• Partnership at the regional and local level to address vast differential testing patterns and close the gap globally

Portfolio Launch Operations Lead

• Drive launch excellence in meeting critical launch milestones and launch stage gates

• Global Governance Lead: Lead cross functional GGTs. Close collaboration with US & ICO counterparts both within the Global Governance Team (GGT) and regular engagement with a co-creation mindset for designing a launch platform and all associated assets

• Ensure synergy and drive operational efficiency across launch assets

• Contribute to the annual Global Operating Plan and Tactical Plan

Prifetrastat Patient Lead

• Develop and lead strategic framework for global patient communications

• Distill patient insight